Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Rectal cancer sub-clones respond differentially to neoadjuvant therapy.

Frydrych LM, Ulintz P, Bankhead A, Sifuentes C, Greenson J, Maguire L, Irwin R, Fearon ER, Hardiman KM.

Neoplasia. 2019 Sep 12;21(10):1051-1062. doi: 10.1016/j.neo.2019.08.004. [Epub ahead of print]

2.

Patient-Reported Unmet Needs in Colorectal Cancer Survivors After Treatment for Curative Intent.

Vu JV, Matusko N, Hendren S, Regenbogen SE, Hardiman KM.

Dis Colon Rectum. 2019 Jul;62(7):815-822. doi: 10.1097/DCR.0000000000001326.

PMID:
31188182
3.

Surgical management of primary colonic lymphoma: Big data for a rare problem.

Maguire LH, Geiger TM, Hardiman KM, Regenbogen SE, Hopkins MB, Muldoon RL, Ford MM, Hawkins AT.

J Surg Oncol. 2019 Sep;120(3):431-437. doi: 10.1002/jso.25582. Epub 2019 Jun 11.

PMID:
31187517
4.

Clinical and pathological outcomes of induction chemotherapy before neoadjuvant radiotherapy in locally-advanced rectal cancer.

Hardiman KM, Antunez AG, Kanters A, Schuman AD, Regenbogen SE.

J Surg Oncol. 2019 Aug;120(2):308-315. doi: 10.1002/jso.25474. Epub 2019 Apr 16.

5.

Patient-Reported Outcomes and Readmission after Ileostomy Creation in Older Adults.

Kandagatla P, Nikolian VC, Matusko N, Mason S, Regenbogen SE, Hardiman KM.

Am Surg. 2018 Nov 1;84(11):1814-1818.

PMID:
30747639
6.

Can ZEB2 Be Used as a Molecular Marker for Risk Stratification of Patients With Colorectal Cancer?

Vu JV, De Roo A, Hardiman KM.

JAMA Netw Open. 2018 Oct 5;1(6):e183133. doi: 10.1001/jamanetworkopen.2018.3133. No abstract available.

PMID:
30646215
7.

Biology of Nodal Spread in Colon Cancer: Insights from Molecular and Genetic Studies.

Kandagatla P, Maguire LH, Hardiman KM.

Eur Surg Res. 2018;59(5-6):361-370. doi: 10.1159/000494832. Epub 2018 Dec 11. Review.

PMID:
30537705
8.

Prevention and Management of Colostomy Complications: Retraction and Stenosis.

Suwanabol PA, Hardiman KM.

Dis Colon Rectum. 2018 Dec;61(12):1344-1347. doi: 10.1097/DCR.0000000000001246. No abstract available.

PMID:
30399047
9.

Update on Sporadic Colorectal Cancer Genetics.

Hardiman KM.

Clin Colon Rectal Surg. 2018 May;31(3):147-152. doi: 10.1055/s-0037-1602234. Epub 2018 Apr 1. Review.

10.

Translational Research in Colorectal Cancer.

Hardiman KM.

Clin Colon Rectal Surg. 2018 May;31(3):145-146. doi: 10.1055/s-0037-1617415. Epub 2018 Apr 1. No abstract available.

11.

Lymph Node Metastases in Colon Cancer Are Polyclonal.

Ulintz PJ, Greenson JK, Wu R, Fearon ER, Hardiman KM.

Clin Cancer Res. 2018 May 1;24(9):2214-2224. doi: 10.1158/1078-0432.CCR-17-1425. Epub 2017 Dec 4.

12.

BRAFV600E cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis.

Sakamoto N, Feng Y, Stolfi C, Kurosu Y, Green M, Lin J, Green ME, Sentani K, Yasui W, McMahon M, Hardiman KM, Spence JR, Horita N, Greenson JK, Kuick R, Cho KR, Fearon ER.

Elife. 2017 Jan 10;6. pii: e20331. doi: 10.7554/eLife.20331.

13.

Patient autonomy-centered self-care checklist reduces hospital readmissions after ileostomy creation.

Hardiman KM, Reames CD, McLeod MC, Regenbogen SE.

Surgery. 2016 Nov;160(5):1302-1308. doi: 10.1016/j.surg.2016.05.007. Epub 2016 Jun 16.

14.

Iron Uptake via DMT1 Integrates Cell Cycle with JAK-STAT3 Signaling to Promote Colorectal Tumorigenesis.

Xue X, Ramakrishnan SK, Weisz K, Triner D, Xie L, Attili D, Pant A, Győrffy B, Zhan M, Carter-Su C, Hardiman KM, Wang TD, Dame MK, Varani J, Brenner D, Fearon ER, Shah YM.

Cell Metab. 2016 Sep 13;24(3):447-461. doi: 10.1016/j.cmet.2016.07.015. Epub 2016 Aug 18.

15.

HIF-3α1 promotes colorectal tumor cell growth by activation of JAK-STAT3 signaling.

Xue X, Jungles K, Onder G, Samhoun J, Győrffy B, Hardiman KM.

Oncotarget. 2016 Mar 8;7(10):11567-79. doi: 10.18632/oncotarget.7272.

16.

Colorectal cancer outcomes and treatment patterns in patients too young for average-risk screening.

Abdelsattar ZM, Wong SL, Regenbogen SE, Jomaa DM, Hardiman KM, Hendren S.

Cancer. 2016 Mar 15;122(6):929-34. doi: 10.1002/cncr.29716. Epub 2016 Jan 25.

17.

Intra-tumor genetic heterogeneity in rectal cancer.

Hardiman KM, Ulintz PJ, Kuick RD, Hovelson DH, Gates CM, Bhasi A, Rodrigues Grant A, Liu J, Cani AK, Greenson JK, Tomlins SA, Fearon ER.

Lab Invest. 2016 Jan;96(1):4-15. doi: 10.1038/labinvest.2015.131. Epub 2015 Nov 16.

18.

Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.

Ziemke EK, Dosch JS, Maust JD, Shettigar A, Sen A, Welling TH, Hardiman KM, Sebolt-Leopold JS.

Clin Cancer Res. 2016 Jan 15;22(2):405-14. doi: 10.1158/1078-0432.CCR-15-0829. Epub 2015 Sep 14.

19.

Rapamycin inhibition of polyposis and progression to dysplasia in a mouse model.

Hardiman KM, Liu J, Feng Y, Greenson JK, Fearon ER.

PLoS One. 2014 Apr 24;9(4):e96023. doi: 10.1371/journal.pone.0096023. eCollection 2014.

20.

Sigmoid diverticulitis: a systematic review.

Morris AM, Regenbogen SE, Hardiman KM, Hendren S.

JAMA. 2014 Jan 15;311(3):287-97. doi: 10.1001/jama.2013.282025. Review.

PMID:
24430321
21.

Surgery for diverticulitis in the 21st century: a systematic review.

Regenbogen SE, Hardiman KM, Hendren S, Morris AM.

JAMA Surg. 2014 Mar;149(3):292-303. doi: 10.1001/jamasurg.2013.5477. Review.

PMID:
24430164
22.

Effect of surgical approach on 30-day mortality and morbidity after elective colectomy: a NSQIP study.

Cone MM, Herzig DO, Diggs BS, Rea JD, Hardiman KM, Lu KC.

J Gastrointest Surg. 2012 Jun;16(6):1212-7. doi: 10.1007/s11605-012-1860-3. Epub 2012 Mar 9.

PMID:
22402957
23.

Specialized practice reduces inpatient mortality, length of stay, and cost in the care of colorectal patients.

Rea JD, Lu KC, Diggs BS, Cone MM, Hardiman KM, Herzig DO.

Dis Colon Rectum. 2011 Jul;54(7):780-6. doi: 10.1007/DCR.0b013e31821484d2.

PMID:
21654243
24.

Disparities in the treatment of colon cancer in octogenarians.

Hardiman KM, Cone M, Sheppard BC, Herzig DO.

Am J Surg. 2009 May;197(5):624-8. doi: 10.1016/j.amjsurg.2008.12.018.

PMID:
19393356
25.

What to do when the pathology from last week's laparoscopic cholecystectomy is malignant and T1 or T2.

Hardiman KM, Sheppard BC.

J Gastrointest Surg. 2009 Nov;13(11):2037-9. doi: 10.1007/s11605-009-0809-7. Epub 2009 Feb 14. No abstract available.

PMID:
19219515
26.

Regulation of amiloride-sensitive Na(+) transport by basal nitric oxide.

Hardiman KM, McNicholas-Bevensee CM, Fortenberry J, Myles CT, Malik B, Eaton DC, Matalon S.

Am J Respir Cell Mol Biol. 2004 May;30(5):720-8. Epub 2003 Nov 7.

PMID:
14607816
27.

Regulation of ion channel structure and function by reactive oxygen-nitrogen species.

Matalon S, Hardiman KM, Jain L, Eaton DC, Kotlikoff M, Eu JP, Sun J, Meissner G, Stamler JS.

Am J Physiol Lung Cell Mol Physiol. 2003 Dec;285(6):L1184-9. Review.

28.

Reactive oxygen nitrogen species decrease cystic fibrosis transmembrane conductance regulator expression and cAMP-mediated Cl- secretion in airway epithelia.

Bebok Z, Varga K, Hicks JK, Venglarik CJ, Kovacs T, Chen L, Hardiman KM, Collawn JF, Sorscher EJ, Matalon S.

J Biol Chem. 2002 Nov 8;277(45):43041-9. Epub 2002 Aug 22.

29.

Modification of sodium transport and alveolar fluid clearance by hypoxia: mechanisms and physiological implications.

Hardiman KM, Matalon S.

Am J Respir Cell Mol Biol. 2001 Nov;25(5):538-41. Review. No abstract available.

PMID:
11713094
30.

Lack of amiloride-sensitive transport across alveolar and respiratory epithelium of iNOS(-/-) mice in vivo.

Hardiman KM, Lindsey JR, Matalon S.

Am J Physiol Lung Cell Mol Physiol. 2001 Sep;281(3):L722-31.

Supplemental Content

Loading ...
Support Center